Avaliação do potencial anticâncer do derivado benzotiazólico (E)-2-((2-(benzo[d]tiazo-2-ila)hidrazono)metil)-4-nitrofenol em células de melanoma humano

Abstract

Malignant melanoma is one of the few cancers has been increasing in prevalence and mortality worldwide. It affects mainly white populations, however, all ethnic groups are affected to some extent. Increased understanding of the causes, progression, and in particular, genes that affect the development of cancer enable improvements in tools for detecting and treating cancer, however, despite significant advances in understanding the biology of melanoma, no changes in practices involved in both approaches and therapies to treat advanced disease. Thus, malignant melanoma has been intensively investigated due to its high metastatic potential. Many patients, when diagnosed with metastatic melanoma have already, which is the leading cause of death among them. This tumor is almost insensitive to standard regimens of chemotherapy, and the chemotherapeutic agents available are limited. Some mutations are known in cutaneous melanomas and N-Ras, Tp16 and Tp53, however, changes in B-Raf significantly exceed the frequency of the other mutations (40-50%). In this context, this project explored the possible mechanisms of action of the derivative benzotiazólico (E)-2-((2-(Benzo[d] thiazole-2-ila)hydrazono) methyl)-4-nitrophenol on cell viability, the activity clonogenic, motility and invasiveness in melanoma cell lines SK-Mel-19, SK-Mel-28 and SK-Mel-103 that have different characteristics from mutations in the genes responsible for the control of cellular homeostasis, as Tp53 and B-Raf. The results of tests performed showed an IC50 at 72hours between (4.87and>10 um) and a possible selective toxicity to the gene mutated B-Raf. Other tests showed induction of cell death by apoptosis, impaired motility and invasiveness of cells treated with SK-Mel benzotiazolic derivative (E)-2-((2-(Benzo[d]thiazole-2-Ila)hydrazono)methyl)-4-nitrophenol. The obtained results make this target compound for more research to use against cancer.